Cryoglobulinemia medical therapy

Cryoglobulinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cryoglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cryoglobulinemia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cryoglobulinemia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cryoglobulinemia medical therapy
CDC on Cryoglobulinemia medical therapy
Cryoglobulinemia medical therapy in the news
Blogs on Cryoglobulinemia medical therapy
Directions to Hospitals Treating Cryoglobulinemia
Risk calculators and risk factors for Cryoglobulinemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Medical Therapy

• The main indication for therapy is progressive end organ disease.

Acute Pharmacotherapies

• Outside of the acute setting, immunosuppresive agents are thought to worsen the course of MC associated with HCV.

  • Interferon-alfa and ribavirin have been used in combination.

• MC response, predictably, was related to the response rate of the underlying HCV to these agents.
• Ribavirin should not be used in patients with glomerular filtration rate (GFR) <50 cc/min.

References

Template:WikiDoc Sources